Deutsche Bank AG Has $2.03 Million Stock Position in Aurinia Pharmaceuticals Inc $AUPH

Key Points

• Deutsche Bank AG significantly increased its stake in Aurinia Pharmaceuticals by 76.7%, owning 252,446 shares worth approximately $2.03 million as of its latest SEC filing.
• Aurinia Pharmaceuticals reported an earnings per share (EPS) of $0.16 for the last quarter, missing the consensus estimate of $0.17, while revenue reached $70.01 million.
• Research analysts currently have a consensus rating of "Buy" for Aurinia Pharmaceuticals, with price targets ranging from $9.00 to $17.00.

Deutsche Bank AG increased its holdings in shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Free Report) TSE: AUP by 76.7% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 252,446 shares of the biotechnology company's stock after buying an additional 109,577 shares during the quarter. Deutsche Bank AG owned 0.18% of Aurinia Pharmaceuticals worth $2,030,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. GF Fund Management CO. LTD. bought a new stake in shares of Aurinia Pharmaceuticals in the fourth quarter worth about $27,000. Tower Research Capital LLC TRC grew its position in shares of Aurinia Pharmaceuticals by 368.5% in the 4th quarter. Tower Research Capital LLC TRC now owns 3,350 shares of the biotechnology company's stock valued at $30,000 after purchasing an additional 2,635 shares during the period. Vermillion & White Wealth Management Group LLC acquired a new position in shares of Aurinia Pharmaceuticals in the 4th quarter valued at approximately $31,000. GAMMA Investing LLC increased its stake in Aurinia Pharmaceuticals by 56.1% during the 1st quarter. GAMMA Investing LLC now owns 4,852 shares of the biotechnology company's stock worth $39,000 after purchasing an additional 1,744 shares in the last quarter. Finally, Natixis acquired a new stake in Aurinia Pharmaceuticals during the 4th quarter worth approximately $49,000. 36.83% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Kevin Tang bought 200,000 shares of the company's stock in a transaction that occurred on Tuesday, August 5th. The shares were acquired at an average price of $11.68 per share, for a total transaction of $2,336,000.00. Following the completion of the acquisition, the director owned 11,329,500 shares of the company's stock, valued at approximately $132,328,560. The trade was a 1.80% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders bought a total of 1,300,000 shares of company stock valued at $13,590,000 over the last 90 days. 12.20% of the stock is currently owned by insiders.

Analyst Ratings Changes

AUPH has been the subject of several research analyst reports. Royal Bank Of Canada upped their price target on shares of Aurinia Pharmaceuticals from $8.00 to $9.00 and gave the company an "outperform" rating in a report on Friday, August 1st. HC Wainwright reaffirmed a "buy" rating and issued a $17.00 price objective on shares of Aurinia Pharmaceuticals in a research report on Wednesday, July 30th. Three research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Aurinia Pharmaceuticals presently has a consensus rating of "Buy" and a consensus price target of $12.00.

Aurinia Pharmaceuticals Stock Performance

Shares of AUPH opened at $12.08 on Friday. The stock has a market capitalization of $1.59 billion, a price-to-earnings ratio of 28.09 and a beta of 1.23. Aurinia Pharmaceuticals Inc has a 12 month low of $6.42 and a 12 month high of $12.53. The firm has a fifty day simple moving average of $9.39 and a 200 day simple moving average of $8.50. The company has a current ratio of 5.23, a quick ratio of 4.63 and a debt-to-equity ratio of 0.18.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last issued its quarterly earnings results on Thursday, July 31st. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.17 by ($0.01). Aurinia Pharmaceuticals had a net margin of 23.31% and a return on equity of 20.06%. The business had revenue of $70.01 million during the quarter, compared to analyst estimates of $64.27 million. Aurinia Pharmaceuticals has set its FY 2025 guidance at EPS. Research analysts forecast that Aurinia Pharmaceuticals Inc will post 0.11 EPS for the current fiscal year.

Aurinia Pharmaceuticals Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.

Want to see what other hedge funds are holding AUPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Free Report) TSE: AUP.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.